BioInnovation Solutions and USAMRIID Develop DNA Sequencing Technology for Rapid Detection and Biosurveillance of Ebola Virus
LAUSANNE, Switzerland and FORT DETRICK, Maryland (PRWEB) October 09, 2014 -- BioInnovation Solutions SA, a Lausanne based company and pioneer in pathogen sequencing analysis assays and software, has announced with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) the development and testing of a sequence-based platform for rapid detection and surveillance of filoviruses such as Ebola and Marburg. The timely study, carried out under a Cooperative Research and Development Agreement (CRADA), will be published in the prestigious journal PLOS one. USAMRIID’s success using the Bioinnovation multiplex platform highlights the importance of biosurveillance as an early warning system, not only to prevent outbreaks such as the ongoing Ebola outbreak in West Africa, but also to provide an improved response capacity. This study will proceed further to develop sequence-based detection technologies to discover new host biomarkers and biothreats at preclinical levels.
BioInnovations DxSeq™ integrated with the Illumina MIseq next-generation sequencing system (NGS) was used to sequence filoviruses, including Ebola, Reston and Marburg, obtained from endemic areas. The combination of BioInnovation’s platform agnostic technology with any next-generation sequencing platform (including systems from Ion Torrent and Illumina) enables much faster and earlier detection of viral and bacterial pathogens and the discovery of new, previously unidentified strains.
“We are pleased with the success of this study, especially in light of the current Ebola outbreak and the declaration of a Global Emergency by the WHO,” said Pat Beyer, CEO of BioInnovation Solutions. “It is our hope that this technology can be deployed to the endemic areas as an early warning system for future outbreaks.”
About BioInnovation Solutions SA
Bioinnovation combines the power of informatics analysis and next-generation DNA sequencing to revolutionize pathogen detection and enable real-time biosurveillance. Its DxSeq™ platform offers new applications in health services through rapid multiplex identification of pathogens and drug resistance genes, providing personalized diagnosis for infectious diseases. BioInnovation’s high throughput pathogen detection system performs rapid and highly sensitive detection of a wide variety of biomarkers using just a common assay protocol. For more information, email pbeyer(at)bioinnova.ch. http://www.bioinnova.ch
About USAMRIID
USAMRIID's mission is to protect the warfighter from biological threats and to be prepared to investigate disease outbreaks or threats to public health. Research conducted at USAMRIID leads to medical solutions-vaccines, drugs, diagnostics, and information-that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
Pat Beyer, BioInnovation, +41 788363306, [email protected]
Share this article